In the past week, GERN stock has gone down by -1.62%, with a monthly decline of -4.49% and a quarterly plunge of -13.27%. The volatility ratio for the week is 3.75%, and the volatility levels for the last 30 days are 4.74% for Geron Corp. The simple moving average for the last 20 days is -3.98% for GERN stock, with a simple moving average of 18.31% for the last 200 days.
Is It Worth Investing in Geron Corp. (NASDAQ: GERN) Right Now?
Moreover, the 36-month beta value for GERN is 0.50. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GERN is 552.62M and currently, short sellers hold a 14.66% of that float. On October 11, 2024, GERN’s average trading volume was 8.91M shares.
GERN) stock’s latest price update
Geron Corp. (NASDAQ: GERN) has seen a decline in its stock price by -1.85 in relation to its previous close of 4.33. However, the company has experienced a -1.62% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-23 that Geron’s imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise in treating MDS and MF, with significant clinical trial results and manageable adverse events. Geron’s financials are strong with a $2.8bn market cap and cash runway until 2026, positioning it well for future growth.
Analysts’ Opinion of GERN
Many brokerage firms have already submitted their reports for GERN stocks, with Leerink Partners repeating the rating for GERN by listing it as a “Outperform.” The predicted price for GERN in the upcoming period, according to Leerink Partners is $7 based on the research report published on September 09, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see GERN reach a price target of $4.50. The rating they have provided for GERN stocks is “Neutral” according to the report published on April 30th, 2024.
TD Cowen gave a rating of “Buy” to GERN, setting the target price at $10 in the report published on April 29th of the current year.
GERN Trading at -5.03% from the 50-Day Moving Average
After a stumble in the market that brought GERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.41% of loss for the given period.
Volatility was left at 4.74%, however, over the last 30 days, the volatility rate increased by 3.75%, as shares sank -5.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.67% lower at present.
During the last 5 trading sessions, GERN fell by -1.16%, which changed the moving average for the period of 200-days by +86.46% in comparison to the 20-day moving average, which settled at $4.43. In addition, Geron Corp. saw 101.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GERN starting from GRETHLEIN ANDREW J, who sale 674,348 shares at the price of $4.56 back on Jul 08 ’24. After this action, GRETHLEIN ANDREW J now owns 0 shares of Geron Corp., valued at $3,073,004 using the latest closing price.
Feller Faye, the EVP, Chief Medical Officer of Geron Corp., sale 287,900 shares at $4.63 during a trade that took place back on Jun 10 ’24, which means that Feller Faye is holding 0 shares at $1,334,129 based on the most recent closing price.
Stock Fundamentals for GERN
Current profitability levels for the company are sitting at:
- -165.6 for the present operating margin
- -21.13 for the gross margin
The net margin for Geron Corp. stands at -159.91. The total capital return value is set at -0.66. Equity return is now at value -72.56, with -50.78 for asset returns.
Based on Geron Corp. (GERN), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -2.45. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is -32.45.
Currently, EBITDA for the company is -192.91 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 1845.5. The receivables turnover for the company is 0.44for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.61.
Conclusion
To wrap up, the performance of Geron Corp. (GERN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
